NO20082684L - F-, G-, H-, I- og K-krystallformer av imatinibmesylat - Google Patents

F-, G-, H-, I- og K-krystallformer av imatinibmesylat

Info

Publication number
NO20082684L
NO20082684L NO20082684A NO20082684A NO20082684L NO 20082684 L NO20082684 L NO 20082684L NO 20082684 A NO20082684 A NO 20082684A NO 20082684 A NO20082684 A NO 20082684A NO 20082684 L NO20082684 L NO 20082684L
Authority
NO
Norway
Prior art keywords
crystal form
crystal forms
imatinib mesylate
warm
preparation
Prior art date
Application number
NO20082684A
Other languages
English (en)
Inventor
Michael Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0524062A external-priority patent/GB0524062D0/en
Priority claimed from GB0524061A external-priority patent/GB0524061D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20082684L publication Critical patent/NO20082684L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

Oppfinnelsen vedrører F-krystallformen, G-krystallformen, H-krystallformen, I-krystallformen og K-krystallformen av metansulfonsyreaddisjonssaltet av 4-(4-metylpiperazin-1-ylmetyl)-N-[4-metyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)fenyl]benzamid, visse prosesser for deres fremstilling, farmasøytiske sammensetninger som inneholder disse krystallformer, deres anvendelse i diagnostiske fremgangsmåter eller for den terapeutiske behandlingen av varmblodige dyr, og deres anvendelse som et intermediat eller for fremstilling av farmasøytiske fremstillinger for anvendelse i diagnostiske fremgangsmåter eller for den terapeutiske behandlingen av varmblodige dyr, spesielt mennesker.
NO20082684A 2005-11-25 2008-06-16 F-, G-, H-, I- og K-krystallformer av imatinibmesylat NO20082684L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0524062A GB0524062D0 (en) 2005-11-25 2005-11-25 Organic compounds
GB0524061A GB0524061D0 (en) 2005-11-25 2005-11-25 Organic compounds
US74001605P 2005-11-28 2005-11-28
US74001705P 2005-11-28 2005-11-28
US74001805P 2005-11-28 2005-11-28
PCT/EP2006/011240 WO2007059963A1 (en) 2005-11-25 2006-11-23 F,g,h,i and k crystal forms of imatinib mesylate

Publications (1)

Publication Number Publication Date
NO20082684L true NO20082684L (no) 2008-08-15

Family

ID=37847165

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082684A NO20082684L (no) 2005-11-25 2008-06-16 F-, G-, H-, I- og K-krystallformer av imatinibmesylat

Country Status (13)

Country Link
US (6) US7893076B2 (no)
EP (3) EP1960380A1 (no)
JP (2) JP5844508B2 (no)
KR (4) KR20130140909A (no)
CN (1) CN102351842B (no)
AU (2) AU2006316823A1 (no)
BR (1) BRPI0618993A2 (no)
CA (3) CA2824301C (no)
EC (1) ECSP088473A (no)
MY (1) MY146403A (no)
NO (1) NO20082684L (no)
UY (1) UY29964A1 (no)
WO (1) WO2007059963A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047530A1 (es) * 2004-02-04 2006-01-25 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida
CA2824301C (en) * 2005-11-25 2016-01-12 Novartis Ag F, g, h, i and k crystal forms of imatinib mesylate
WO2009042809A1 (en) * 2007-09-25 2009-04-02 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions
CZ2009570A3 (cs) 2009-08-26 2011-03-09 Zentiva, K. S. Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
EP2536707A1 (en) 2010-02-15 2012-12-26 Reliance Life Sciences Pvt., Ltd. Process for the preparation of alpha form of imatinib mesylate
PL390611A1 (pl) 2010-03-04 2011-09-12 Tomasz Koźluk Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
WO2012090221A1 (en) 2010-12-29 2012-07-05 Cadila Healthcare Limited Novel salts of imatinib
EP2604596A1 (en) * 2011-12-16 2013-06-19 Deva Holding Anonim Sirketi Polymorphs of imatinib
CA2877030A1 (en) 2012-06-22 2013-12-27 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
KR101242955B1 (ko) * 2012-06-25 2013-03-12 제일약품주식회사 이마티닙 메실레이트 결정형 α의 제조 방법
EP2803353B1 (en) 2013-05-14 2018-05-23 Hetero Research Foundation Compositions of Imatinib
WO2015081175A1 (en) * 2013-11-26 2015-06-04 Children's Medical Center Corporation Expandable stent valve
WO2018089404A1 (en) 2016-11-11 2018-05-17 Mallinckrodt Nuclear Medicine Llc Processes for generating germanium-68 with reduced volatiles
JP7263784B2 (ja) 2019-01-11 2023-04-25 日本精工株式会社 自在継手用ヨーク

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (no) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US20060073185A1 (en) 2002-12-13 2006-04-06 Bausch & Lomb Incorporated Method and composition for contact lenses
US7300938B2 (en) * 2003-06-02 2007-11-27 Hetero Drugs Limited Polymorphs of imatinib mesylate
AR047530A1 (es) 2004-02-04 2006-01-25 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida
CA2555804C (en) * 2004-02-11 2012-06-26 Natco Pharma Limited Polymorphic form of imatinib mesylate and a process for its preparation
UA84462C2 (ru) 2004-04-02 2008-10-27 Институт Фармацевтични Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой
BRPI0511805A (pt) 2004-06-04 2008-01-15 Bioniche Life Sciences Inc uso de imatinib para tratar distúrbios hepáticos e infecções virais
WO2006024863A1 (en) * 2004-09-02 2006-03-09 Cipla Limited Stable crystal form of imatinib mesylate and process for the preparation thereof
WO2006048890A1 (en) * 2004-11-04 2006-05-11 Sun Pharmaceutical Industries Limited Imatinib mesylate crystal form and process for preparation thereof
WO2006054314A1 (en) 2004-11-17 2006-05-26 Natco Pharma Limited Polymorphic forms of imatinib mesylate
US9804295B2 (en) 2005-05-05 2017-10-31 Novartis Ag Ophthalmic devices for sustained delivery of active compounds
GB0511066D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
AR055613A1 (es) * 2005-08-26 2007-08-29 Novartis Ag Formas cristalinas delta y epsilon de mesilato de imatinib
CA2824301C (en) * 2005-11-25 2016-01-12 Novartis Ag F, g, h, i and k crystal forms of imatinib mesylate

Also Published As

Publication number Publication date
US20110171301A1 (en) 2011-07-14
ECSP088473A (es) 2008-06-30
US20080268040A1 (en) 2008-10-30
KR20130141712A (ko) 2013-12-26
KR20130140909A (ko) 2013-12-24
KR20130137721A (ko) 2013-12-17
CA2824301C (en) 2016-01-12
MY146403A (en) 2012-08-15
JP2014074067A (ja) 2014-04-24
AU2006316823A1 (en) 2007-05-31
EP2546248A1 (en) 2013-01-16
JP2009517353A (ja) 2009-04-30
EP1960380A1 (en) 2008-08-27
CA2628330C (en) 2015-06-16
US7893076B2 (en) 2011-02-22
US8633213B2 (en) 2014-01-21
CA2824307C (en) 2016-03-29
CN102351842B (zh) 2014-07-23
KR20080078804A (ko) 2008-08-28
UY29964A1 (es) 2007-06-29
US20120015955A1 (en) 2012-01-19
US8592440B2 (en) 2013-11-26
CA2824307A1 (en) 2007-05-31
CN102351842A (zh) 2012-02-15
EP2578580A1 (en) 2013-04-10
AU2011201286A1 (en) 2011-04-07
WO2007059963A1 (en) 2007-05-31
CA2824301A1 (en) 2007-05-31
US20130224288A1 (en) 2013-08-29
US8846706B2 (en) 2014-09-30
US8507515B2 (en) 2013-08-13
CA2628330A1 (en) 2007-05-31
US8198289B2 (en) 2012-06-12
JP5844508B2 (ja) 2016-01-20
US20120226038A1 (en) 2012-09-06
US20120015027A1 (en) 2012-01-19
BRPI0618993A2 (pt) 2011-09-20

Similar Documents

Publication Publication Date Title
NO20082684L (no) F-, G-, H-, I- og K-krystallformer av imatinibmesylat
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
NO20064584L (no) Tetrahydropyridoindolderivater
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
NO20066055L (no) Pyridinderivater
NO20081211L (no) Xantinderivater som selektive HM74A agonister
MX2009013272A (es) Formas amorfas estabilzadas de mesilato de imatinib.
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20050828L (no) lndol-3-svovelderivater
NO20090628L (no) Pyridizinon derivativater
NO20051726L (no) Pyrimidinonderivaer som terapeutiske midler ovenfor akutte og kroniske inflammasjons-, iskemiske og remodeleringsprosesser
NO20076635L (no) Krystallinske og andre former for 4-amino-5-fluor-3-[6-(4-metylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-kinolin-2-on-melkesyresalter
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
NO20071197L (no) Sulfonamidderivater, deres fremstilling og deres terapeutiske anvendelse
NO20051165L (no) Benzotiazolderivater som har -adrenoerseptorantagonist aktivitet
NO20064015L (no) Kondenserte derivater av pyrazol
NO20075992L (no) Forbindelser som modulerer C-Kit og C-FMS aktivitet og anvendelser derav
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
NO20063748L (no) Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer
UA95199C2 (en) Aqueous formulation of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application